Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...